<?xml version="1.0" encoding="UTF-8"?>
<p>Of the 32 patients with symptoms and anti-CHIKV IgG positivity in the bDMARD group, 28% had symptoms lasting more than three months, while in the control group, this presentation occurred in 64.2% of subjects (
 <italic>p</italic>=0.021). When analyzed by bDMARD class and compared with the control group, only the patients using anti-TNF biologicals showed statically significant difference (
 <italic>p</italic> &lt; 0.001) (
 <xref rid="tab2" ref-type="table">Table 2</xref>).
</p>
